trending Market Intelligence /marketintelligence/en/news-insights/trending/65ui-SA8X5Z-QgpI_Vu_Uw2 content esgSubNav
In This List

Eli Lilly breast cancer drug gets US FDA priority review stamp

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Eli Lilly breast cancer drug gets US FDA priority review stamp

Eli Lilly & Co. said the U.S. Food and Drug Administration granted priority review designation for its new drug application for Verzenio to treat breast cancer.

The application was based on the positive interim results of the MONARCH 3 study on Verzenio, or abemaciclib, combined with an aromatase inhibitor as initial endocrine-based therapy for treating women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

Lilly had completed the EU and Japan regulatory submissions for the drug during the third quarter.

About 252,710 new cases of invasive breast cancer are expected to be diagnosed in the U.S. in women in 2017.